Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data

References

• Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133(4):364–374. doi: 10.1111/j.1365-2141.2006.06024.x.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group. Blood. 2009;113(11):2386–2393. doi: 10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hanau A, Hatfield M, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. J Med Econ. 2020;23(2):184–192. doi: 10.1080/13696998.2019.1669329.
   PubMed Web of Science ®Google Scholar
• Liang Y, Rascati K, Richards K. Prevalence of primary immune thrombocytopenia and related healthcare resource utilization among Texas Medicaid beneficiaries. Curr Med Res Opin. 2021;37(8):1315–1322. doi: 10.1080/03007995.2021.1923469.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi: 10.1182/blood-2010-08-302984.
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi: 10.1182/bloodadvances.2019000966.
   PubMed Web of Science ®Google Scholar
• Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285–1305. doi: 10.1007/s40265-021-01553-7.
   PubMed Web of Science ®Google Scholar
• Pulanić D, Bátorová A, Bodó I, et al. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Ann Hematol. 2023;102(4):715–727. doi: 10.1007/s00277-023-05114-8.
   PubMed Web of Science ®Google Scholar
• Lal LS, Said Q, Andrade K, et al. Second-line treatments and outcomes for immune thrombocytopenia: a retrospective study with electronic health records. Res Pract Thromb Haemost. 2020;4(7):1131–1140. doi: 10.1002/rth2.12423.
   PubMed Web of Science ®Google Scholar
• Forsythe A, Schneider J, Pham T, et al. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. J Comp Eff Res. 2020;9(7):447–457. doi: 10.2217/cer-2019-0177.
   PubMed Web of Science ®Google Scholar
• Stafkey-Mailey D, Lokhandwala T, Said Q, et al. Comparison of adherence, persistence, and bleed-related event rates in patients diagnosed with immune thrombocytopenia and treated with thrombopoietin receptor agonists. Value Health. 2018;21(suppl 1):S261. doi: 10.1016/j.jval.2018.04.1743.
   Google Scholar
• McGrath LJ, Kilpatrick K, Overman RA, et al. Treatment patterns among adults with primary immune thrombocytopenia diagnosed in hematology clinics in the United States. Clin Epidemiol. 2020;12:435–445. doi: 10.2147/CLEP.S229266.
   PubMed Web of Science ®Google Scholar
• Palandri F, Rossi E, Bartoletti D, et al. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood. 2021;138(7):571–583. doi: 10.1182/blood.2021010735.
   PubMed Web of Science ®Google Scholar
• Cuker A, Despotovic JM, Grace RF, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2020;5(1):69–80. doi: 10.1002/rth2.12457.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123. doi: 10.3324/haematol.2018.212845.
   PubMed Web of Science ®Google Scholar
• Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016;128(12):1547–1554. doi: 10.1182/blood-2016-03-603365.
   PubMed Web of Science ®Google Scholar
• Stasi R, Murali M, Michel M, et al. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. Int J Hematol. 2012;96(1):26–33. doi: 10.1007/s12185-012-1088-8.
   PubMed Web of Science ®Google Scholar
• Altomare I, Cetin K, Wetten S, et al. Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US. Clin Epidemiol. 2016;8:231–239.
   PubMed Web of Science ®Google Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost. 2016;116(5):975–986.
   PubMed Web of Science ®Google Scholar
• United States Census Bureau. Census regions and divisions of the United States. 2010 [cited 2023 Oct 1]. Available from: https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf
   Google Scholar
• Glasheen WP, Cordier T, Gumpina R, et al. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188–197.
   PubMed Web of Science ®Google Scholar
• Patwardhan P, Landsteiner A, Lal LS, et al. Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis. Ann Hematol. 2022;101(1):11–19. doi: 10.1007/s00277-021-04637-2.
   PubMed Web of Science ®Google Scholar
• McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388–3414. doi: 10.1002/sim.5753.
   PubMed Web of Science ®Google Scholar
• Kang DYJ, Schafer JL. Demystifying double robustness: a comparison of alternative strategies for estimating a population mean from incomplete data. Statist Sci. 2007;22(4):523539. doi: 10.1214/07-STS227.
   Web of Science ®Google Scholar
• Wang J, Li Y, Wang C, et al. Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis. Biomed Res Int. 2018;2018:1316096. doi: 10.1155/2018/1316096.
   PubMed Web of Science ®Google Scholar
• Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–e81. doi: 10.1016/S2352-3026(15)00003-4.
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–464. doi: 10.1111/jth.12813.
   PubMed Web of Science ®Google Scholar
• Catalá-López F, Corrales I, de la Fuente-Honrubia C, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: an updated systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc). 2015;145(12):511–519. doi: 10.1016/j.medcli.2015.03.014.
   PubMed Web of Science ®Google Scholar
• Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124–1135. doi: 10.3324/haematol.2019.218883.
   PubMed Web of Science ®Google Scholar
• American Society of Hematology. Covid-19 and ITP: frequently asked questions. [cited 2022 Mar 28]. Available from: https://www.hematology.org/covid-19/covid-19-and-itp
   Google Scholar